Aurinia Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies to treat autoimmune and rare diseases
The company is dedicated to advancing its pipelines, particularly in developing treatments for conditions such as lupus nephritis, with a commitment to improving patient outcomes through scientifically driven solutions. Aurinia’s goal is to bring forward novel medications that address unmet medical needs and transform the standard of care in its therapeutic areas.
Over the past three months, Mainz has seen a staggering 2,500% increase in message volume on Stocktwits, while Aurinia’s engagement has grown just 23%.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Aurinia Pharmaceuticals, Inc. (NASDAQ: AUPH) shares are trending on social media Friday. The company provided its preliminary, unaudited fourth-quarter and fiscal year 2023 financial results. What To Know:
On CNBC’s "Mad Money Lightning Round," Jim Cramer said BP (NYSE: BP) is "not great, not bad." He added, "This whole group is going through a real re-evaluation.
Gainers Addentax Group Corp. (NASDAQ: ATXG) shares jumped 47.3% to $9.68. Addentax Group is launching automation of artificial intelligence internet operational tools project with top Games-as-a-Service firms.
Gainers Renalytix Plc (NASDAQ: RNLX) shares surged 48.7% to $3.02 in pre-market trading after the company received FDA De Novo marketing authorization for its KidneyIntelX.dkd prognostic test.
